BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/20/2021 7:18:39 AM | Browse: 376 | Download: 451
 |
Received |
|
2021-05-06 19:53 |
|
Peer-Review Started |
|
2021-05-06 19:57 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-12 03:53 |
|
Revised |
|
2021-06-22 01:53 |
|
Second Decision |
|
2021-08-30 03:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-08-30 08:28 |
|
Articles in Press |
|
2021-08-30 08:28 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-10-18 03:53 |
|
Publish the Manuscript Online |
|
2021-10-20 07:18 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Aditi Jain and Vikas Bhardwaj |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Vikas Bhardwaj, PhD, Assistant Professor, Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, 130 South 9th Street, Philadelphia, PA 19107, United States. vikas.bhardwaj@jefferson.edu |
| Key Words |
Pancreatic cancer; Metabolism; DNA repair; Therapy-resistance; Immunotherapy |
| Core Tip |
With a five-year survival rate of 10%, pancreatic adenocarcinomas are one of the most aggressive forms of cancer. Despite extensive efforts, only a few drug combinations have been found to be effective in improving patient outcomes. The drug-resistant mechanisms active in pancreatic ductal adenocarcinoma contribute to the ineffectiveness of therapies. Through this review, we discuss key mechanisms that contribute to the development of resistant phenotype in pancreatic tumors and how these mechanisms are being sought as a target to treat this cancer. |
| Publish Date |
2021-10-20 07:18 |
| Citation |
Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J Gastroenterol 2021; 27(39): 6527-6550 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i39/6527.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i39.6527 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
